99 related articles for article (PubMed ID: 12181075)
1. Regarding the loss of CD20 after rituximab therapy.
Lee R; Braylan RC
Br J Haematol; 2002 Sep; 118(3):927. PubMed ID: 12181075
[No Abstract] [Full Text] [Related]
2. Apparent modulation of CD20 by rituximab: an alternative explanation.
Cragg MS; Bayne MC; Illidge TM; Valerius T; Johnson PW; Glennie MJ
Blood; 2004 May; 103(10):3989-90; author reply 3990-1. PubMed ID: 15121717
[No Abstract] [Full Text] [Related]
3. CD20-targeted therapy: the next generation of antibodies.
van Meerten T; Hagenbeek A
Semin Hematol; 2010 Apr; 47(2):199-210. PubMed ID: 20350667
[TBL] [Abstract][Full Text] [Related]
4. New monoclonal antibody approved as lymphoma therapy.
Am J Health Syst Pharm; 1998 Jan; 55(2):110. PubMed ID: 9465971
[No Abstract] [Full Text] [Related]
5. Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia.
D'Auria F; Guariglia R; Villani O; Mansueto G; Grieco V; Zonno A; Bianchino G; Di Giovannantonio L; Vita G; Musto P
Clin Ther; 2010 Oct; 32(11):1911-6. PubMed ID: 21095486
[TBL] [Abstract][Full Text] [Related]
6. Rituximab not affected by statins?
Pharmacogenomics; 2009 Feb; 10(2):259. PubMed ID: 19207027
[No Abstract] [Full Text] [Related]
7. Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts.
Ringshausen I; Feuerstacke Y; Krainz P; den Hollander J; Hermann K; Buck A; Peschel C; Meyer Zum Bueschenfelde C
Cancer Res; 2010 Jun; 70(11):4292-6. PubMed ID: 20460536
[TBL] [Abstract][Full Text] [Related]
8. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
Pels H; Schulz H; Schlegel U; Engert A
Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.
Al-Zoobi L; Salti S; Colavecchio A; Jundi M; Nadiri A; Hassan GS; El-Gabalawy H; Mourad W
Int Immunol; 2014 Aug; 26(8):451-65. PubMed ID: 24894009
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis and effect on CD20+ using rituximab on autologous peripheral blood stem cell harvests from patients with B cell lymphomas.
Borbolla-Escoboza JR; Leon MI; Collados MT; Baez E; Baltasar S; Hernández R; Rojas JC
Stem Cells Dev; 2004 Apr; 13(2):193-6. PubMed ID: 15186735
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in rheumatic diseases.
Saraux A; Devauchelle V; Jousse S; Youinou P
Joint Bone Spine; 2007 Jan; 74(1):4-6. PubMed ID: 17178461
[No Abstract] [Full Text] [Related]
13. Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.
Ferreri AJ; Dognini GP; Verona C; Patriarca C; Doglioni C; Ponzoni M
Haematologica; 2007 Jan; 92(1):e1-2. PubMed ID: 17405748
[TBL] [Abstract][Full Text] [Related]
14. [Anti-CD20 in hematologic oncology].
Milpied N
Presse Med; 2009 May; 38(5):788-98. PubMed ID: 19297126
[TBL] [Abstract][Full Text] [Related]
15. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
Wyen C; Jensen B; Hentrich M; Siehl J; Sabranski M; Esser S; Gillor D; Müller M; Van Lunzen J; Wolf T; Bogner JR; Wasmuth JC; Christ H; Fätkenheuer G; Hoffmann C
AIDS; 2012 Feb; 26(4):457-64. PubMed ID: 22112600
[TBL] [Abstract][Full Text] [Related]
16. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.
Schmitz K; Brugger W; Weiss B; Kaiserling E; Kanz L
Br J Haematol; 1999 Aug; 106(2):571-2. PubMed ID: 10460626
[No Abstract] [Full Text] [Related]
17. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.
Stel AJ; Ten Cate B; Jacobs S; Kok JW; Spierings DC; Dondorff M; Helfrich W; Kluin-Nelemans HC; de Leij LF; Withoff S; Kroesen BJ
J Immunol; 2007 Feb; 178(4):2287-95. PubMed ID: 17277134
[TBL] [Abstract][Full Text] [Related]
18. The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.
Cheadle EJ; Sidon L; Dovedi SJ; Melis MH; Alduaij W; Illidge TM; Honeychurch J
Br J Haematol; 2013 Sep; 162(6):842-5. PubMed ID: 23772929
[No Abstract] [Full Text] [Related]
19. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.
Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M
Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: mechanism of action and resistance.
Maloney DG; Smith B; Rose A
Semin Oncol; 2002 Feb; 29(1 Suppl 2):2-9. PubMed ID: 11842383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
